Detection of pancreatic cancer using serum protein profiling

HPB

Volumn 15, Issue 8, 2013, Pages 602-610

  Velstra, Berit ^a   Bonsing, Bert A ^a   Mertens, Bart J ^b   Van Der Burgt, Yuri E M ^b   Huijbers, Anouck ^a   Vasen, Hans ^a   Mesker, Wilma E ^a   Deelder, André M ^b   Tollenaar, Rob A E M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Biolomolecular Mass Spectometry Unit   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMA PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; BLOOD SAMPLING; CALIBRATION; CANCER DIAGNOSIS; CATION EXCHANGE; CLINICAL EVALUATION; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PANCREAS CANCER; PROTEIN ANALYSIS; PROTEIN ISOLATION; SENSITIVITY AND SPECIFICITY; SERUM PROTEIN PROFILING; SOLID PHASE EXTRACTION;

EID: 84880161321     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12017     Document Type: Conference Paper

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Siegel R, Ward E, Brawley O, Jemal A,. (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
3. Wong T, Howes N, Threadgold J, Smart HL, Lombard MG, Gilmore I, et al. (2001) Molecular diagnosis of early pancreatic ductal adenocarcinoma in high-risk patients. Pancreatology 1: 486-509.
4. Sener SF, Fremgen A, Menck HR, Winchester DP,. (1999) Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 189: 1-7.
5. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, et al. (2005) The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 31: 164-169.
6. Hruban RH, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, Falatko F, et al. (1999) Familial pancreatic cancer. Ann Oncol 10 (Suppl. 4): 69-73.
7. Schenk M, Schwartz AG, O′Neal E, Kinnard M, Greenson JK, Fryzek JP, et al. (2001) Familial risk of pancreatic cancer. J Natl Cancer Inst 93: 640-644.
8. Vasen HF, Gruis NA, Frants RR, van der Velden PA, Hille ET, Bergman W,. (2000) Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 87: 809-811.
9. Werkgroep Klinische Oncogenetica. (1996) Erfelijke Tumoren: 'Richtlijnen voor Diagnostiek en Preventie'. zie ook. Available at http://www.stoet.nl/ uploads/richtlijnenboekje.pdf (last accessed 2010).
10. Vasen HF, Wasser M, van, Mil A, Tollenaar RA, Konstantinovski M, Gruis NA, et al. (2011) Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 140: 850-856.
11. Wulfkuhle JD, Liotta LA, Petricoin EF,. (2003) Proteomic applications for the early detection of cancer. Nat Rev Cancer 3: 267-275.
12. Aebersold R, Mann M,. (2003) Mass spectrometry-based proteomics. Nature 422: 198-207.
13. Nilsson T, Mann M, Aebersold R, Yates JR, III, Bairoch A, Bergeron JJ,. (2010) Mass spectrometry in high-throughput proteomics: ready for the big time. Nat Methods 7: 681-685.
14. de Noo ME, Tollenaar RA, Ozalp A, Kuppen PJ, Bladergroen MR, Eilers PH, et al. (2005) Reliability of human serum protein profiles generated with C8 magnetic beads assisted MALDI-TOF mass spectrometry. Anal Chem 77: 7232-7241.
15. Albrethsen J,. (2007) Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin Chem 53: 852-858.
16. Duncan MW, Aebersold R, Caprioli RM,. (2010) The pros and cons of peptide-centric proteomics. Nat Biotechnol 28: 659-664.
17. Mauri P, Scigelova M,. (2009) Multidimensional protein identification technology for clinical proteomic analysis. Clin Chem Lab Med 47: 636-646.
18. Hu L, Ye M, Zou H,. (2009) Recent advances in mass spectrometry-based peptidome analysis. Expert Rev Proteomics 6: 433-447.
19. Callesen AK, Mohammed S, Bunkenborg J, Kruse TA, Cold S, Mogensen O, et al. (2005) Serum protein profiling by miniaturized solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 19: 1578-1586.
20. Jimenez CR, El FZ, Knol JC, Hoekman K, Kruyt FA, Giaccone G, et al. (2007) Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS. Proteomics Clin Appl 1: 598-604.
21. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, et al. (2004) Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 76: 1560-1570.
22. de Noo ME, Deelder A, van der, Werff M, Ozalp A, Mertens B, Tollenaar R,. (2006) MALDI-TOF serum protein profiling for the detection of breast cancer. Onkologie 29: 501-506.
23. Alagaratnam S, Mertens BJ, Dalebout JC, Deelder AM, van, Ommen GJ, den, Dunnen JT, et al. (2008) Serum protein profiling in mice: identification of factor XIIIa as a potential biomarker for muscular dystrophy. Proteomics 8: 1552-1563.
24. Nadarajah VD, Mertens BJA, Dalebout H, Bladergroen M, Alagaratnam S, Bushby K, et al. (2012) Serum peptide profiles of Duchenne Muscular Dystrophy (DMD) patients evaluated by data handling strategies for high resolution content. J Proteomics Bioinf 5: 96-103.
25. de Noo ME, Mertens BJ, Ozalp A, Bladergroen MR, van der, Werff MP, van de, Velde CJ, et al. (2006) Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur J Cancer 42: 1068-1076.
26. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577.
27. Navaglia F, Fogar P, Basso D, Greco E, Padoan A, Tonidandel L, et al. (2009) Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry. Clin Chem Lab Med 47: 713-723.
28. Sun ZL, Zhu Y, Wang FQ, Chen R, Peng T, Fan ZN, et al. (2007) Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers. Biochim Biophys Acta 1774: 764-771.
29. Kakisaka T, Kondo T, Okano T, Fujii K, Honda K, Endo M, et al. (2007) Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J Chromatogr B Analyt Technol Biomed Life Sci 852: 257-267.
30. Deng R, Lu Z, Chen Y, Zhou L, Lu X,. (2007) Plasma proteomic analysis of pancreatic cancer by 2-dimensional gel electrophoresis. Pancreas 34: 310-317.
31. Ehmann M, Felix K, Hartmann D, Schnolzer M, Nees M, Vorderwulbecke S, et al. (2007) Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 34: 205-214.
32. Honda K, Hayashida Y, Umaki T, Okusaka T, Kosuge T, Kikuchi S, et al. (2005) Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res 65: 10613-10622.
33. Yu KH, Rustgi AK, Blair IA,. (2005) Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Proteome Res 4: 1742-1751.
34. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, et al. (2004) Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 10: 860-868.
35. Mertens BJ, de Noo ME, Tollenaar RA, Deelder AM,. (2006) Mass spectrometry proteomic diagnosis: enacting the double cross-validatory paradigm. J Comput Biol 13: 1591-1605.
36. Mertens BJA, Burgt van der YEM, Velstra B, Mesker WE, Deelder AM, Tollenaar RAEM,. (2011) On the use of double cross-validation for the combination of proteomic mass spectral data for enhanced diagnosis and prediction. Stat Probab Lett 81: 759-766.
37. Zapico-Muniz E, Farre-Viladrich A, Rico-Santana N, Gonzalez-Sastre F, Mora-Brugues J,. (2010) Standardized peptidome profiling of human serum for the detection of pancreatic cancer. Pancreas 39: 1293-1298.
38. Cecconi D, Palmieri M, Donadelli M,. (2011) Proteomics in pancreatic cancer research. Proteomics 11: 816-828.
39. Pawa N, Wright JM, Arulampalam TH,. (2010) Mass spectrometry based proteomic profiling for pancreatic cancer. JOP 11: 423-426.
40. Chen JH, Ni RZ, Xiao MB, Guo JG, Zhou JW,. (2009) Comparative proteomic analysis of differentially expressed proteins in human pancreatic cancer tissue. Hepatobiliary Pancreat Dis Int 8: 193-200.
41. Liu D, Cao L, Yu J, Que R, Jiang W, Zhou Y, et al. (2009) Diagnosis of pancreatic adenocarcinoma using protein chip technology. Pancreatology 9: 127-135.
42. Guo J, Wang W, Liao P, Lou W, Ji Y, Zhang C, et al. (2009) Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Sci 100: 2292-2301.
43. Diamandis EP,. (2004) Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 96: 353-356.
44. Goonetilleke KS, Siriwardena AK,. (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33: 266-270.
45. Tiss A, Smith C, Menon U, Jacobs I, Timms JF, Cramer R,. (2010) A well-characterised peak identification list of MALDI MS profile peaks for human blood serum. Proteomics 10: 3388-3392.
46. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, et al. (2006) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116: 271-284.
47. Koomen JM, Shih LN, Coombes KR, Li D, Xiao LC, Fidler IJ, et al. (2005) Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 11: 1110-1118.
48. Albrethsen J,. (2011) The first decade of MALDI protein profiling: a lesson in translational biomarker research. J Proteomics 74: 765-773.